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Abstract 
Review on ALK-rearranged renal cell carcinoma, 
summarizing clinical and genetic data 
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Identity 
Phylum 
Urinary system:Kidney: Renal cell tumors: :ALK-
rearranged renal cell carcinoma 
Classification 
ALK-rearranged renal cell carcinoma is a distinct 
type of renal cell carcinoma included in the so-called 
emerging/provisional RCC. The 2013 International 
Society of Urological Pathology (ISUP) Vancouver 
Classification of (adult) renal neoplasia identified a 
category of emerging or provisional new entities. 
Although these entities appeared to be distinct, these 
are rare tumors not fully characterized and additional 
reports will be needed to refine their diagnostic 
criteria and established clinical outcome. 
Clinics and pathology 
Disease 
ALK-rearranged renal cell carcinoma is a distinct 
emerging type of RCC that commonly affects 
children and young adults. The disease is defined as 
a RCC harboring ALK gene rearrangements, 
resulting in oncogenic fusions with a variety of 
partner genes. 
Epidemiology 
ALK-rearranged renal cell carcinoma is an 
uncommon type of RCC. Initially described in 
children, in which it may be over-represented, 
further investigations demonstrated that a small 
proportion of adult RCC belong to this ALK-
rearranged category. Of 18 well-documented cases 
reported to date, 8 have been described in children 
(6-16 yo), and 10 in adults (33-61 yo). An 
association with sickle cell trait was observed in the 
first cases described, but this association seems 
inconsistent and may be limited to cases with a 
specific VCL/ALK gene fusion. 
Clinics 
These form masses in the kidney. The majority of 
cases described so far have been confined to the 
kidney with a median size of 4.5 cm. Nodal 
extension at presentation has been observed; distant 
metastases are rare and have been observed more 
commonly in adult patients. The clinical course of 
ALK-rearranged RCC is frequently indolent, 
although rare cases, more frequently in adult 
patients, pursue a more aggressive clinical course. 
Pathology 
Grossly, ALK-rearranged RCC are brown to tan 
solid masses that may be well circumscribed or 
Kidney: ALK-rearranged renal cell carcinoma  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(6) 261 
 
infiltrative, usually located centrally with extension 
into the renal pelvis. Histologically, the tumors most 
commonly feature a solid architecture, with 
occasional trabecular and tubular features, and are 
composed of sheets of epithelioid cells with 
abundant palely eosinophilic cytoplasm and frequent 
intracytoplasmic lumina. Cell nuclei show high-
grade features, with vesicular chromatin and 
prominent nucleoli -usually ISUP grade 3, but 
occasionally ISUP grade 4. Rhabdoid morphology or 
intracytoplasmic inclusions may be focally present. 
There is a prominent capillary network. Less 
frequently, ALK-rearranged RCC may show a 
predominantly papillary architecture, mucin 
deposition and focal psammomatous calcification. It 
is unclear if some of this features correlate with 
specific fusion partners. Immunohistochemically, 
the tumor cells consistently express ALK, CK7, 
EMA, and TFE3 (which should not be interpreted as 
evidence of TFE3 rearrangement, absent in this 
tumor type); nuclear INI1 expression is retained. 
Treatment 
Treatment: surgical excision. Treatment with ALK 
inhibitors has provided clinical benefit in cases with 
advanced disease. 
Cytogenetics 
Cytogenetics Morphological 
ALK Gene Fusions in renal cell carcinoma (RCC) 
Neoplasm Fusion Age Range (years) (n) 
ALK-rearranged RCC t(2;10)(p23;q22) VCL/ALK 6-16 (3) 
ALK-rearranged RCC t(1;2)(q25;p23) TPM3/ALK 12-49 (7) 
ALK-rearranged RCC inv(2)(p22p23) STRN/ALK 33,38 (2) 
ALK-rearranged RCC inv(2)(p21p23) EML4/ALK 52,53 (2) 
ALK-rearranged RCC t(1;2)(p32;p23) HOOK1/ALK 16 (1) 
ALK-rearranged RCC ALK/unknown 44-61 (3) 
 
Result of the chromosomal 
anomaly 
Fusion Protein 
Description 
ALK-rearranged RCC are characterized by fusion of 
the ALK tyrosine kinase gene with one of several 
gene partners including VCL, TPM3, STRN, EML4, 
and HOOK1 (Table 1). The originally described 
translocation in ALK-rearranged RCC was 
t(2;10)(p23;q22) which fuses the 5' end  of VCL to 
the 3' end of ALK. So far, VCL/ALK fusions have 
been described only in ALK-rearranged RCC -
interestingly, in 3 tumors affecting pediatric patients 
with sickle cell trait. Similarly, HOOK1/ALK fusion 
has been identified only in RCC. The TPM3/ALK, 
STRN/ALK and EML4/ALK gene fusions, 
however, are similar to those found in other tumor 
types such as inflammatory myofibroblastic 
sarcoma, thyroid carcinoma and lung 
adenocarcinoma. All of these ALK gene fusions 
result in oncogenic proteins that include the kinase 
domain of ALK, fused to structural protein motifs 
that enable direct or indirect oligomerization. The 
ALK fusion partners also contribute active 
promoters that lead to strong expression of ALK, 
which can be detected by immunohistochemistry. 
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